BRPI0711481A8 - derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens - Google Patents

derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens

Info

Publication number
BRPI0711481A8
BRPI0711481A8 BRPI0711481A BRPI0711481A BRPI0711481A8 BR PI0711481 A8 BRPI0711481 A8 BR PI0711481A8 BR PI0711481 A BRPI0711481 A BR PI0711481A BR PI0711481 A BRPI0711481 A BR PI0711481A BR PI0711481 A8 BRPI0711481 A8 BR PI0711481A8
Authority
BR
Brazil
Prior art keywords
derivatives
dihydrotetrabenzene
radiolabeled
imaging agents
imaging
Prior art date
Application number
BRPI0711481A
Other languages
English (en)
Inventor
M Skovronsky Daniel
F Kung Hank
Kung Mei-Ping
Kilbourn Michael
Original Assignee
Univ Michigan Regents
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents, Univ Pennsylvania filed Critical Univ Michigan Regents
Publication of BRPI0711481A2 publication Critical patent/BRPI0711481A2/pt
Publication of BRPI0711481A8 publication Critical patent/BRPI0711481A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems

Abstract

derivados radiomarcados de diidro-tetrabenazina e seu uso como agente de imagens. este invento se refere a um método de imagem de transportadores vesiculares de monoamina e a compostos marcados e composições farmacêuticas deles, e métodos de tornar os compostos marcados úteis para obter imagem de transportadores vesiculares de monoamina. este invento também se refere a compostos e métodos de monitorar a progressão de uma doença relacionada com os transportadores vesiculares de monoamina.
BRPI0711481A 2006-05-02 2007-05-01 derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens BRPI0711481A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79651806P 2006-05-02 2006-05-02
US60/796,518 2006-05-02
US90811607P 2007-03-26 2007-03-26
US60/908,116 2007-03-26
PCT/US2007/010478 WO2007130365A2 (en) 2006-05-02 2007-05-01 Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents

Publications (2)

Publication Number Publication Date
BRPI0711481A2 BRPI0711481A2 (pt) 2011-11-16
BRPI0711481A8 true BRPI0711481A8 (pt) 2017-11-28

Family

ID=38668238

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711481A BRPI0711481A8 (pt) 2006-05-02 2007-05-01 derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens

Country Status (19)

Country Link
US (1) US8562949B2 (pt)
EP (2) EP2604290A3 (pt)
JP (1) JP5392622B2 (pt)
KR (1) KR101429302B1 (pt)
CN (1) CN101484190B (pt)
AU (1) AU2007248764B2 (pt)
BR (1) BRPI0711481A8 (pt)
CA (1) CA2650904C (pt)
DK (1) DK2012833T3 (pt)
ES (1) ES2525932T3 (pt)
IL (1) IL195044A (pt)
MX (1) MX2008014064A (pt)
NO (1) NO341065B1 (pt)
PL (1) PL2012833T3 (pt)
PT (1) PT2012833E (pt)
SI (1) SI2012833T1 (pt)
TW (1) TWI432214B (pt)
WO (1) WO2007130365A2 (pt)
ZA (1) ZA200810200B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008500B2 (en) 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
US7897769B2 (en) 2007-10-25 2011-03-01 General Electric Company Intermediates for fluorinated dihydrotetrabenazine ether imaging agents and probes
US7897770B2 (en) 2007-10-25 2011-03-01 General Electric Company Fluorinated dihydrotetrabenazine ether imaging agents and probes
JP5663309B2 (ja) * 2007-10-25 2015-02-04 ゼネラル・エレクトリック・カンパニイ フッ素化ジヒドロテトラベナジンエーテルイメージング剤及びプローブ
WO2009058851A2 (en) * 2007-10-31 2009-05-07 Alseres Pharmaceuticals, Inc. Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
US8053578B2 (en) * 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
US7902364B2 (en) 2007-11-29 2011-03-08 General Electric Company Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US7910738B2 (en) 2007-11-29 2011-03-22 General Electric Company Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US7919622B2 (en) 2007-12-07 2011-04-05 Kande Kankanamalage Dayarathna Amarasinghe Intermediates for fluorinated tetrabenazine carbinol compounds imaging agents and probes
US8013161B1 (en) 2007-12-07 2011-09-06 General Electric Company Fluoroalkyl tetrabenazine carbinol compounds as imaging agents and probes
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
DK3061760T3 (en) * 2008-09-18 2018-02-05 Auspex Pharmaceuticals Inc DEUTERATED BENZOQUINOLIZIN DERIVATIVES AS INHIBITORS OF VESICULAR MONOAMIN TRANSPORT 2
CN102307858B (zh) * 2009-03-19 2015-01-21 国立大学法人京都大学 胰岛成像用分子探针前体及其使用
CN102120742B (zh) * 2010-01-08 2013-03-13 中国药科大学 一种丁苯那嗪的制备方法
EP2394668A1 (en) * 2010-06-01 2011-12-14 Julius-Maximilians-Universität Würzburg PET radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CN101985446B (zh) * 2010-06-10 2012-05-30 江苏省原子医学研究所 一种(±)-9-O-去甲基-α-二氢丁苯那嗪合成方法
US9289516B2 (en) * 2011-03-09 2016-03-22 The General Hospital Corporation Imaging beta cell mass
CN102260255B (zh) * 2011-07-07 2013-07-10 江苏省原子医学研究所 一种9,10-二甲氧基-1,3,4,6,7,11b-六氢-3-异丁基-2H-苯并[a]喹嗪-2-酮的简便合成方法
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
IN2015DN01662A (pt) 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc
CN102936246A (zh) * 2012-11-08 2013-02-20 江苏暨明医药科技有限公司 丁苯那嗪的合成方法
MX2015009719A (es) 2013-01-31 2016-08-08 Auspex Pharmaceuticals Inc Inhibidores benzoquinolona de vmat2.
US20160207917A1 (en) * 2013-09-27 2016-07-21 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2015077521A1 (en) * 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
MX2016006622A (es) * 2013-11-22 2016-12-09 Auspex Pharmaceuticals Inc Metodos para tratar actividad muscular anormal.
KR102391134B1 (ko) 2013-12-03 2022-04-28 오스펙스 파마슈티칼스, 인코포레이티드 벤조퀴놀린 화합물을 제조하는 방법
US20160346270A1 (en) 2014-01-27 2016-12-01 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
MX2016010213A (es) 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
IL288712B2 (en) 2015-03-06 2024-01-01 Auspex Pharmaceuticals Inc Methods for treating abnormal movement disorders
BR112018007118A2 (pt) 2015-10-09 2018-12-11 Teva Pharmaceuticals Int Gmbh método para tratar um distúrbio de deficiência de dopamina, método para melhorar o tempo motor ativo sem discinesia num paciente com doença de parkinson, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir o tempo motor inativo num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir flutuações de nível de dopamina estriatal num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina após um tratamento de longo prazo, composição farmacêutica e embalagem
TW201906818A (zh) * 2017-05-31 2019-02-16 美商５１１製藥公司 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
CN108912118A (zh) * 2018-07-12 2018-11-30 新乡学院 一种四氢异喹啉并三嗪骨架化合物及其制备方法
CA3148302A1 (en) * 2019-08-12 2021-02-18 Shandong Luye Pharmaceutical Co., Ltd. Vmat2 inhibitor and preparation method therefor and use thereof
CN111320620A (zh) * 2020-03-17 2020-06-23 四川大学华西医院 一种异喹啉并哒嗪酮类化合物及其合成方法和应用
CA3207452A1 (en) 2021-03-22 2022-09-29 Nicole Harriott Vmat2 inhibitors and methods of use
CN114288419B (zh) * 2021-12-30 2023-08-18 中山大学附属第八医院（深圳福田） 一种利福平纳米递药系统的制备及其在防治帕金森病方面的应用
CN115536705A (zh) * 2022-09-23 2022-12-30 江苏省原子医学研究所 靶向ii型囊泡单胺转运体分子探针及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3053845A (en) 1962-09-11 Benzofykedocolines
DE1470074C3 (de) * 1964-07-25 1974-01-24 Merck Patent Gmbh, 6100 Darmstadt 1,2,3,4,6,7-Hexahydro-l lbH-benzo eckige Klammer auf a eckige Klammer zu chinolizine sowie deren Acetate und/oder phsiologisch verträgliche Säureadditionssalze sowie Verfahren zu ihrer Herstellung
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US5278308A (en) * 1992-02-28 1994-01-11 The Trustees Of The University Of Pennsylvania Iodine derivatives of tetrabenazine
FR2770215B1 (fr) 1997-10-28 2000-01-14 Pf Medicament Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
NO20085004L (no) 2009-02-02
ES2525932T3 (es) 2015-01-02
US20080050312A1 (en) 2008-02-28
CA2650904C (en) 2015-07-07
EP2604290A2 (en) 2013-06-19
PL2012833T3 (pl) 2015-05-29
EP2012833A2 (en) 2009-01-14
ZA200810200B (en) 2012-02-29
EP2604290A3 (en) 2013-07-10
AU2007248764B2 (en) 2013-08-01
IL195044A (en) 2013-08-29
PT2012833E (pt) 2014-12-23
CN101484190A (zh) 2009-07-15
EP2012833A4 (en) 2011-06-29
SI2012833T1 (sl) 2015-03-31
TWI432214B (zh) 2014-04-01
CN101484190B (zh) 2011-07-20
IL195044A0 (en) 2011-08-01
NO341065B1 (no) 2017-08-14
JP2009535403A (ja) 2009-10-01
AU2007248764A1 (en) 2007-11-15
DK2012833T3 (en) 2015-01-19
CA2650904A1 (en) 2007-11-15
MX2008014064A (es) 2009-06-12
US8562949B2 (en) 2013-10-22
TW200810783A (en) 2008-03-01
KR20090007781A (ko) 2009-01-20
BRPI0711481A2 (pt) 2011-11-16
WO2007130365A3 (en) 2008-11-27
EP2012833B1 (en) 2014-10-29
JP5392622B2 (ja) 2014-01-22
KR101429302B1 (ko) 2014-08-11
WO2007130365A2 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
BRPI0711481A8 (pt) derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens
CY1119048T1 (el) Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
MA32369B1 (fr) Composes de benzene sulfonamide thiazole et oxazole
ECSP088666A (es) Derivados de las benzamidas y heteroarenos
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
CU23614B7 (es) Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
GT200600346A (es) Nueva fórmula cristalina v de la agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
CL2008001868A1 (es) Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
UY30711A1 (es) Nuevos derivados de 1,4-benzotiepina-1, 1-cioxido, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.-
CU20060037A7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
UY31870A (es) Receptor metabotrópico de glutamato potenciadores 286
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
ECSP088971A (es) Ligandos 101 de los receptores nicotínicos de acetilcolina
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
GT200900026A (es) Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements